Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Infusion Time Differences and Patient Satisfaction with Intravenous Immunoglobulin(IVIg)for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Japan.(Time to Motion study)

X
Trial Profile

Infusion Time Differences and Patient Satisfaction with Intravenous Immunoglobulin(IVIg)for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Japan.(Time to Motion study)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 04 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Chronic inflammatory demyelinating polyradiculoneuropathy
  • Focus Therapeutic Use
  • Sponsors CSL Behring
  • Most Recent Events

    • 20 Jul 2022 Status changed from active, no longer recruiting to completed.
    • 23 Dec 2021 Planned End Date changed from 30 Sep 2021 to 30 Nov 2021.
    • 23 Dec 2021 Status has been changed to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top